Ocular Symptoms and Signs with Preserved and Preservative-Free Glaucoma Medications

Jaenen, N; Baudouin, C; Pouliquen, P; Manni, Gianluca; Figueiredo, Américo; Zeyen, Thierry

doi:10.1177/112067210701700311

Cited by 364 publications

(292 citation statements)

References 24 publications

Supporting

Mentioning

254

Contrasting

Unclassified

Order By: Relevance

“…Statistically significant changes were observed for every symptom (p<0.05) except frequent blinking (p=0.291). Improvement in the frequency of symptoms with preservative free medication in glaucoma patients has also been reported by Pisella et al, Jaenen et al and Uusitalo et al [18][19][20] Results of the present study were in accordance with the results of previously conducted studies.…”

Section: Frequency Of Symptomssupporting

confidence: 83%

A comparative study of benzalkonium chloride-free latanoprost versus benzalkonium chloride-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma

Chhabra

Gupta

Singh

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Prolonged use of anti-glaucoma therapy leads to development of ocular surface disease (OSD). The purpose of this study was to compare the effect of Benzalkonium chloride (BKC)-free latanoprost and Benzalkonium chloride (BKC)-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma (POAG).Methods: This was a prospective, open-label, randomized, interventional, switch trial. 30 established cases of POAG who were already on BKC-preserved latanoprost for atleast more than three months were enrolled. Their Schirmer test and Tear film break-up time (TBUT) were recorded at the baseline. They were required to answer an ocular surface disease index (OSDI) questionnaire from which an OSDI score was calculated. They were switched to BKC-free latanoprost for another three months. On their follow-up visit at 6 weeks and 12 weeks, Schirmer test and Tear film break up time were performed again and OSDI score was calculated.Results: Schirmer test increased from 6.73±3.77 mm at baseline to 9.53±3.67 mm at 6 weeks and 11.97±3.53 mm at 12 weeks (p=0.001). Mean TBUT improved significantly from 6.77±3.82 seconds at baseline to 8.63±3.91 seconds at 6 weeks to 10.47±3.76 seconds at 12 weeks (p=0.001). OSDI score decreased from 31.55±23.32 at baseline to 23.42±21.93 at 6 weeks to 15.82±20.10 at 12 weeks (p=0.001).Conclusions: BKC-free latanoprost led to improvement in tear film status or ocular surface health of glaucoma patients as compared to BKC-preserved latanoprost.

show abstract

Section: Frequency Of Symptomssupporting

confidence: 83%

A comparative study of benzalkonium chloride-free latanoprost versus benzalkonium chloride-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma

Chhabra

Gupta

Singh

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Decreased tolerance due to the presence of BAK usually only manifests after long periods of chronic use, and is often related to BAK-induced increased incidence of ocular surface disease 18 . In this study, however, there was no difference in tolerance between the groups, which may reflect the short treatment period (42 days) in this study and the small number of patients.…”

Section: Preservative-free Versus Preserved Latanoprost Eye Dropsmentioning

confidence: 99%

“…Glaucoma requires long-term, chronic treatment. As such, preservative-free treatments which are better tolerated than preserved treatments could lead to better therapeutic adherence 16,17 due to the lower incidence of adverse events 18 . This phase II, pilot study was conducted prior to further clinical development of a preservative-free latanoprost formulation to compare the diurnal efficacy, safety, and pharmacokinetics of the preservative-free formulation versus a preserved latanoprost formulation in newly diagnosed patients with open-angle glaucoma or ocular hypertension.…”

Section: Introductionmentioning

confidence: 99%

Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension

Aptel

Choudhry

Stalmans

2016

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: This study compared the efficacy, safety, and pharmacokinetics of a preservative-free latanoprost formulation to an established, benzalkonium chloride (BAK) containing formulation for the treatment of open-angle glaucoma or ocular hypertension. Methods: This was a phase II, randomized, cross-over, investigator-masked, multi-center, pilot study (NCT01494753). A total of 30 untreated adult patients (aged !18 years) with primary open angle glaucoma, pseudo-exfoliative glaucoma, pigmentary glaucoma, or ocular hypertension received either preservative-free or preserved latanoprost once daily in both eyes for 6 weeks, before crossing over to receive the other treatment. Efficacy (intraocular pressure [IOP] at 8 am, midday, 4 pm and 8 pm, and global efficacy assessment by investigator), safety (adverse events, ocular symptoms and global tolerance, slit lamp examination, funduscopy, visual field examination, visual acuity, and heart rate), and pharmacokinetics were assessed at Days 0, 42, and 84. Results: Both treatments resulted in a reduction in IOP that was similar for the preservative-free and the preserved formulation at all time points. Similarly, the overall diurnal reduction was similar in both groups (6.3 mmHg [27.9% reduction] and 6.4 mmHg [28.1% reduction] for preserved and preservativefree latanoprost, respectively). There were no differences in global efficacy assessment or in the safety and tolerance of each treatment. Systemic concentrations of latanoprost were very low; AUC 0-30 and C max were lower and t max was longer for preservative-free latanoprost. Conclusions: Preservative-free latanoprost showed similar efficacy at all time points compared to BAK preservative containing formulation, with no difference in tolerance, allowing progression to phase III clinical development. ARTICLE HISTORY

show abstract

“…Клинические проявления наблюдаются с часто-той до 50 %, что существенно выше, чем у лиц без глаукомы. Кроме того, в ходе ряда иссле-дований установлено, что частота глазной сим-птоматики зависит от наличия в составе капель консерванта [29,36] и количества используемых препаратов [32], а прекращение инстилляций существенно снижает выраженность клиниче-ских проявлений [36,45]. Опубликованы данные о развитии субконъюнктивального фиброза у па-циентов, длительное время находящихся на мест-ной терапии, что обусловлено увеличением коли-чества фибробластов в субэпителиальной строме вследствие повышения числа провоспалительных клеток [16,22,41].…”

Section: The Influence Of Local Iop-lowering Therapy On the Anterior unclassified

The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Petrov

Юрьевич²,

Lovpache

et al. 2017

Ophthalmology Reports

View full text Add to dashboard Cite

Nowadays, a wide choice of local IOP-lowering medications allows ensuring a successful intraocular pressure compensation and primary open angle glaucoma stabilization. However, taking into consideration a long term action of drugs on the ocular surface, even without clinical manifestations there is a direct inflammatory cells’ activation with mixed toxic and allergic changes, which is confirmed by histology, immune-histology, and impression cytology methods. Such chronic sub-clinical inflammation represent a potential risk of excessive fibroblast proliferation with subsequent rapid postoperative scarring of new outflow pathways and atypical filtration bleb formation. It is shown that there is a clear relationship between number of glaucoma drugs used, treatment duration, intensity of conjunctival infiltration with inflammatory cells and fibroblasts, and risk of episcleral fibrosis and subconjunctival scarring during post-op period. (For citation: Petrov SYu, Lovpache DzhN, Loskutov IA, Safronova DM. The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery. Ophthalmology Journal. 2017;10(4):41-47. doi: 10.17816/OV10441-47).

show abstract

Ocular Symptoms and Signs with Preserved and Preservative-Free Glaucoma Medications

Abstract: Compared to preserved eyedrops, preservative free eyedrops are significantly less associated with ocular symptoms and signs of irritation.

Cited by 364 publications

References 24 publications

A comparative study of benzalkonium chloride-free latanoprost versus benzalkonium chloride-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma

A comparative study of benzalkonium chloride-free latanoprost versus benzalkonium chloride-preserved latanoprost on ocular surface health in patients of primary open angle glaucoma

Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension

The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Contact Info

Product

Resources

About